ESPERITE (ESP) Q1 consolidated revenue higher compared to budget
EBITDA improved compared to budget as a result of cost control
Zutphen, the Netherlands – 31 May 2017
ESPERITE (ESP) has concluded new agreements with its note holders
Zutphen, the Netherlands – 31 May 2017
Genoma has filed appeal to the decision of liquidation taken on May 4th 2017. Genoma considers this decision arbitrary due to the circumstances of the commercial and legal relationship with Premaitha.
Zutphen, The Netherlands, 19 May 2017
Esperite (ESP) – Esperite confirms the positive development of its current and future genetic activities and announces its intentions to claim 5.2 Million euro damages against Premaitha (NIPT)
Zutphen, The Netherlands, 15 May 2017
Patent granted to Cell Factory in Europe confirms great potential with its exclusive extracellular vesicles in broad therapeutic applications like Crohn’s disease and Type 1 Diabetes.
Zutphen, The Netherlands – 8 November 2016
Genoma on a sharp growth for its strategic expansion
CryoSave fell short due to major changes in workflow
Esperite now with stronger markets positions, but late on schedule.
Zutphen, the Netherlands – 28 April 2016
Genoma continues its intercontinental expansion through a partnership with Intercare, a South African healthcare leader.
Geneva, Switzerland – 9th February 2016
ESPERITE N.V. (Euronext: ESP, ‘ESPERITE’, or ‘the Group’) announces its trading update for the quarter ended 30 September 2015.
Zutphen, The Netherlands – 3 November 2015
ESPERITE N.V. Trading Update. Q1 confirms strategy and forecasted growth with Genoma
The company is now building the future. CryoSave is on track and Genoma shows its ability to support the current published forecasts and ambitious next developments.
Zutphen, The Netherlands – 19 May 2015
TRANQUILITY, the only CE-IVD certified genetic test for trisomies 21, 18 and 13 that provides, sexual aneuploidies, microdeletions and fetal sex detection, now ready for mass market
Geneva, Switzerland – 30 April 2015
